HK Stock Market Move | CLOVER BIO-B(02197) rose more than 16% in early trading, obtaining more positive data in phase 1 clinical trials of RSV vaccine for elderly population.

CLOVER BIO-B (02197) rose by over 16% in the morning session, with a 15.28% increase as of the time of writing, trading at 2.64 Hong Kong dollars, with a trading volume of 21.8247 million Hong Kong dollars. On the news front, Clover Biopharmaceuticals announced that its respiratory syncytial virus (RSV) pre-fusion F protein (PreF) candidate vaccine (SCB-1019) has achieved additional positive data in a Phase I clinical trial conducted in the United States. The trial compared the effectiveness of SCB-1019 with AREXVY for repeat vaccination, and the results showed that the RSV-A and RSV-B neutralizing antibody geometric mean titers (GMT) in the SCB-1019 heterologous repeat vaccination group showed an increase trend of about 60-80%. It is worth noting that Clover Biopharmaceuticals recently announced that Clover Hong Kong and the Global Alliance for Vaccines and Immunization (Gavi) have reached a comprehensive settlement on the arbitration of the COVID-19 vaccine pre-purchase agreement, with the alliance withdrawing all claims. According to the settlement arrangement, the company is required to make a one-time upfront payment of 7 million US dollars, and to bear deferred payments every six months, linked to future cash revenue or contingent payments, with a total payment cap at the mid-range of tens of millions of US dollars, significantly reducing from Gavi's previous claim of 224 million US dollars.